Endocannabinoid and Psychological Responses to Yoga in Healthy Adults

Healthy Clinical Trial

Official title:

Endocannabinoid and Psychological Responses to Yoga in Healthy Adults

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT03710577
• Other study ID #: 2017-0980
• Secondary ID: A176000EDUC/KINE
• Status: Completed
• Phase: N/A
• Start date: December 12, 2017
• Est. completion date: May 16, 2018

Study information

• Verified date: November 2020
• Source: University of Wisconsin, Madison
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study evaluates the acute effect of yoga on plasma levels of endocannabinoids and mood (i.e., mood disturbance, anxiety, pain) compared to one session of quiet rest. Participants completed one session of yoga and one session of quiet rest on two separate days.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 12
• Est. completion date: May 16, 2018
• Est. primary completion date: May 16, 2018
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Female
• Age group: 18 Years to 45 Years

Eligibility

Inclusion Criteria:

• greater than or equal to 18 years old and < 45 years old and
• report being healthy.

Exclusion Criteria:

• Being pregnant or planning to become pregnant,
• currently smoking,
• having a history of light headedness or fainting during blood draws or physical activity,
• having a history of chest pain during physical activity,
• having a bone, joint, cardiac, or other medical condition that a doctor has said may be worsened by physical activity,
• taking medications for any chronic diseases such as high blood pressure or diabetes,
• responding 'Yes' to any of the seven questions on the Par-Q.

Related Conditions & MeSH terms

• Healthy

Intervention

Behavioral:
• Yoga
1 session
• Quiet Rest
1 session

Locations

Country	Name	City	State
United States	University of Wisconsin-Madison Natatorium	Madison	Wisconsin

Sponsors (1)

Lead Sponsor	Collaborator
University of Wisconsin, Madison

Country where clinical trial is conducted

United States, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change in Plasma Concentration of N-arachidonoylethanolamine	Plasma concentration of anandamide, one effector of the endocannabinoid system	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Primary	Change in Plasma Concentration of 2-Arachidonoylglycerol (2-AG)	Plasma concentration of 2-AG, one effector of the endocannabinoid system	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Secondary	Change in Total Mood Disturbance as Measured by the Profile of Mood States	65-item self-reported mood questionnaire that measures mood "right now." Scores range from 0-200 with higher scores indicating higher mood disturbance.	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Secondary	Change in State Anxiety as Measured by the State-Trait Anxiety Inventory	20-item self-reported anxiety questionnaire that measures anxiety "right now." Scores range from 20-80 with higher scores indicating higher anxiety.	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)
Secondary	Change in Total Pain as Measured by the Short-form McGill Pain Questionnaire	15-item self-reported pain questionnaire that measures pain "right now." Scores range from 0-45 with higher scores indicating higher pain.	This will be measured 2 times during each study visit, once before the assigned study task (i.e., baseline) and once upon task completion (i.e., approx. 40 min. later)